Trial Profile
Establish a new algorithm for antiviral therapies based on HCV NS5A mutation status in patients with chronic hepatitis C infection.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 May 2016
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary) ; Peginterferon (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 19 May 2016 New trial record